LPS-RS | Unit size | Cat. code | Docs | Price |
---|---|---|---|---|
LPS from R. sphaeroides | 5 mg | tlrl-rslps | TDSMSDS | Please contact our distributor Add to favorite |
LPS-RS Ultrapure | Unit size | Cat. code | Docs | Price |
---|---|---|---|---|
Ultrapure lipopolysaccharide from R. sphaeroides | 1 mg | tlrl-prslps | TDSMSDS | Please contact our distributor Add to favorite |
Lipopolysaccharide from the photosynthetic bacterium Rhodobacter sphaeroides (LPS-RS) is a potent antagonist of lipopolysaccharide (LPS) from pathogenic bacteria [1]. Complete competitive inhibition of LPS activity is possible at a 100-fold excess of the antagonist. LPS-RS does not induce TLR4 signaling but is detected by the LAL assay, the standard endotoxin detection assay.
InvivoGen provides LPS-RS with two grades of purity:
Reference:
1. Coats SR. et al., 2005. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize Escherichia coli lipopolysaccharide at the TLR4 signaling complex. J Immunol.;175(7):4490-8.2. Hirschfeld M. et al., 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol. 165(2):618-22.
Back to the topSpecificity: TLR4 antagonistLPS-RS standard is also a TLR2 agonist
Working concentration: 10 ng - 10 μg/ml
Endotoxin level: 1 x 106 EU/mg
Solubility: 5 mg/ml in water
InvivoGen provides LPS-RS with two grades of purity: Standard and Ultrapure
Back to the topLPS-RS:
LPS-RS Ultrapure:
LPS-RS is shipped at room temperature
Upon receipt it should be stored at -20 ̊C.Upon resuspension, prepare aliquots of LPS-RS and store at 4°C for short term storage or -20 ̊C for long term storage.
Lyophilized product is stable 1 year at -20°C when properly stored.Resuspended product is stable 1 month at 4°C and 6 months at -20°C.
Avoid repeated freeze-thaw cycles.
Back to the topLPS from the photosynthetic bacterium Rhodobacter sphaeroides (LPS-RS) is the first potent antagonist of toxic LPS in both human and murine cells and also prevents LPS-induced shock in mice [1].
LPS-RS is penta-acylated and as other under-acylated LPS seems to utilize at least two distinct mechanisms to block LPS-dependent activation of TLR4.
The main mechanism consists of direct competition between under-acylated LPS and hexa-acylated LPS for the same binding site on MD-2, while the secondary mechanism involves the ability of under-acylated LPS:MD-2 complexes to inhibit hexa-acylated endotoxin: MD-2 complexes function at TLR4 [2-5].
Complete competitive inhibition of LPS activity is possible at a 100 fold excess of the antagonist. LPS-RS does not induce TLR4 signaling but is detected by the LAL assay, the standard endotoxin detection assay.
LPS-RS preparations (cat. code tlrl-rslps) contain lipopeptide contaminants, and therefore stimulate Toll-like receptor 2 (TLR2).
1. Qureshi, N. et al., 1999. Nontoxic RsDPLA as a potent antagonist of toxic lipopolysaccharide. p. 687-698. In: H. Brade, and S. M. Opal, and S. N. Vogel, and D. C. Morrison, eds. Endotoxin in Health and Disease 687. Marcel Dekker, New York.2. Coats SR. et al., 2005. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize Escherichia coli lipopolysaccharide at the TLR4 signaling complex.J Immunol.;175(7):4490-8.3. Teghanemt A. et al., 2005. Molecular basis of reduced potency of underacylated endotoxins. J Immunol. 175(7):4669-76.4. Visintin A. et al., 2005. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol. 175(10):6465-72.5. Saitoh S. et al., 2004. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol. 16(7):961-9.
Back to the top2020 Eur Neuropsychopharmacol. DOI: 10.1016/j.euroneuro.2019.12.121
Chuang H.G. et al.
2020 J Neuroinflammation. DOI: 10.1186/s12974-019-1690-2
Vargas-Caraveo A. et al.
2019 Sci Rep. DOI: 10.1038/s41598-019-54617-w
Vallance T.M. et al.
2019 Nat Commun. DOI: 10.1038/s41467-019-10766-0
Irmscher S. et al.
2018 Sci Rep. 8(1):7096.
Chentouh R. et al.
2018 Exp Cell Res. 367(2):282-290.
Pantaleão L. et al.
2017 Brain Res. S0006-8993(17)30176-2.
Horie K. et al.
2017 Sci Rep. 7(1):2384.
Serrero M. et al.
2017 J Neurosci. 37(42):10154-10172.
Leduc-Pessah H. et al.
2017 Immunol Cell Biol. 95(5):491-495.
Modhiran N. et al.
2017 FASEB J. 31(5):1891-1902.
Lévêque M. et al.
2017 J Control Release. S0168-3659(17)30690-9.
Tummala H. et al.
2017 J Virol. JVI.00179-17.
Olejnik J. et al.
2016 Exp Cell Res. S0014-4827(16)30385-8.
Herzmann N. et al.
2016 J Neuroimmunol. 291:29-38.
Madeira A, Burgelin I, Perron H, Curtin 2, Lang AB, Faucard R.
2016 Mol Hum Reprod. 22(7):465-74.
Gysler SM. et al.
2016 Arthritis Res Ther. 18(1):264.
Lee JY. et al.
2015 Infect Immun. 83(1):227-38.
Brummelman J, Veerman RE, Hamstra HJ, Deuss AJ, Schuijt TJ, Sloots A, Kuipers B, van Els CA, van der Ley P, Mooi FR, Han WG, Pinelli E.
2015 Sci Transl Med. 7(304):304ra142.
Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, Hume DA, Stacey KJ, Young PR.
2014 J Pain. pii: S1526-5900(14)00678-6
Li Y, Zhang H, Zhang H, Kosturakis AK, Jawad AB, Dougherty PM
2013 J Endocrinol.216(1):61-71.
Lu Z, Zhang X, Li Y, Jin J, Huang Y.
2013 J Immunol. 191(2):922-33
Shalaby KH, Allard-Coutu A, O'Sullivan MJ, Nakada E, Qureshi ST, Day BJ, Martin JG.
2012 FEBS Lett. 586(4):319-24
Murakami K, Tanaka M, Usui T, Kawabata D, Shiomi A, Iguchi-Hashimoto M, Shimizu M, Yukawa N, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Umehara H, Mimori T
Load moreSouthernBiotech/Goat Anti-Human Lambda-Alexa Fluor® 555/2070-32/1.0 mg
vectorlabs/Biotinylated Aleuria Aurantia Lectin (AAL)/B-1395/1 mg
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Mouse IgG)/PK-6102/1 kit
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Universal)/PK-6200/1 kit
vectorlabs/Unconjugated Musa Paradisiaca (Banana) Lectin (BanLec)/L-1410/5 mg
GiottoBiotech/Calmodulin N60D/5 mg/G02CLM60cn